Health and medical announcements from PROT, CBLI, and AZN

crwefinancelogo2

signup3m

PROTEONOMIX, INC. (OTC:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, is pleased to provide an update on the Company's successful international approach to commercializing its proprietary and patent pending stem cell technologies.

Mr. Michael Cohen, Chairman and CEO of Proteonomix, noted:

1. In the past few months the Company has undertaken an intensive international effort to establish strategic joint ventures in several European and Mid-Eastern nations for our Proteonomix Regenerative Translational Medicine Institute, Inc. We may be able to finalize the terms and conditions on at least one agreement arising from this initiative in the short term.

As a reminder, PROT's mission is to translate the most promising internal and external stem cell biology and cellular therapy to clinical applications of regenerative medicine. We have had discussions regarding the creation of clinics in more one than one country and we believe that we may be able to eventually open such regenerative medicine clinics in Europe and/or the Middle East in the coming year.

2. Of course, we intend that such clinics will operate under the strictest cGMP guidelines allowing us to use the clinical information generated for our future discussions with the FDA, which would be helpful in pursuing the more arduous process for eventually establishing regenerative medicine clinics in the United States.

PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging skin care products.

Cleveland BioLabs, Inc. (NASDAQ:CBLI) recently reported that the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (DHHS) exercised the $4.1 million fourth milestone-based option on the Company's existing contract under the Broad Agency Announcement titled, Therapies for Hematopoietic Syndrome, Bone Marrow Stromal Cell Loss, and Vascular Injury Resulting from Acute Exposure to Ionizing Radiation, for selected tasks in the advanced development of Protectan CBLB502. The value of the contract, originally awarded in September 2008, is $15.6 million, including an increase in the first milestone-based option, which was exercised in September 2009.

CBLI is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute.

AstraZeneca (NYSE:AZN) recently reported that as of August 9, the company has reached agreements in principle on monetary terms with attorneys representing approximately 17,500 SEROQUEL product liability claimants in the United States for approximately $198 million. The agreements in principle are subject to agreement on non-monetary terms. As of June 30, 2010, no provision had been made in respect of any settlements. Any provision would be disregarded in calculating Core earnings and, as such, the Company's Core earnings per share guidance for 2010 remains unchanged at $6.35-$6.65.

AZN is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion healthcare business.

http://crwefinance.com/img/crwefinance_new_buscard2.jpg

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)